Page 113 - 中国全科医学2022-18
P. 113

·2286· http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn


                                                                                                 ·论著·


           复方大血藤灌肠剂联合地屈孕酮治疗子宫腺肌病

           腹腔镜术后的临床疗效研究

                                                                                               扫描二维码
                                  1
               1
                                          2
                         1
                                                   1
           应翩 ,王佳曦 ,杨华娣 ,徐利 ,陆申奕 ,吴燕平                        1*                                 查看原文
               【摘要】 背景 子宫腺肌病(AM)是妇科难治性疑难病之一,发病机制尚不明确,个体化治疗目前被广泛重
           视,中西医结合治疗具有优势。目的 观察复方大血藤灌肠剂联合地屈孕酮治疗 AM 腹腔镜术后的临床疗效。方法
           选取 2019 年 1 月至 2020 年 8 月在浙江省中医院经腹腔镜术后病理诊断确诊为 AM 且经中医辨证属瘀热互结型患者 46
           例为研究对象,采用随机方法将患者分为治疗组(24 例)和对照组(22 例)。治疗组使用复方大血藤灌肠剂联合口
           服地屈孕酮;对照组仅口服地屈孕酮。疗程 3 个月,比较两组治疗前和治疗后临床综合疗效、中医症候评分、疼痛程
           度〔采用视觉模拟评分(VAS)进行评估〕、月经量评分〔采用失血量图形分析评分法(PBAC)进行评分〕、子宫体积、
           卵巢功能指标及血清糖类抗原 125(CA125)情况。比较两组疗程结束后 1 年的远期治疗效果。结果 治疗后,治疗
           组临床综合疗效优于对照组(u=2.140,P=0.032)。治疗后治疗组中医症候评分低于对照组(P<0.05)。两组治疗后
           VAS 评分、PBAC 评分、促黄体生成素(LH)、雌二醇(E2)、CA125 低于治疗前,子宫体积小于治疗前(P<0.05)。
           治疗后治疗组 VAS 评分低于对照组,LH、CA125 高于对照组,子宫体积小于对照组(P<0.05)。疗程结束后随访 1 年,
           治疗组复发率为 20.8%(5 例),妊娠率为 8.3%(2 例);对照组复发率为 45.5%(10 例),妊娠率为 9.1%(2 例),
                                                    2
           两组复发率、妊娠率比较,差异均无统计学意义(χ =3.166、0.008,P>0.05)。结论 复方大血藤灌肠剂联合地屈孕
           酮治疗 AM,能降低中医症候评分、缩小子宫体积,减轻疼痛,减少月经量,治疗效果优于单独使用地屈孕酮。
               【关键词】 子宫腺肌病;复方大血藤灌肠剂;地屈孕酮;临床疗效
               【中图分类号】 R 711.71 【文献标识码】 A DOI:10.12114/j.issn.1007-9572.2021.02.122
               应翩,王佳曦,杨华娣,等 . 复方大血藤灌肠剂联合地屈孕酮治疗子宫腺肌病腹腔镜术后的临床疗效研究[J].
           中国全科医学,2022,25(18):2286-2290. [www.chinagp.net]
               YING P,WANG J X,YANG H D,et al. Clinical efficacy of compound Daxueteng enema plus dydrogesterone in post-
           laparoscopic adenomyosis patients with blood stasis-heat syndrome[J]. Chinese General Practice,2022,25(18):2286-
           2290.

           Clinical Efficacy of Compound Daxueteng Enema plus Dydrogesterone in Post-laparoscopic Adenomyosis Patients with
                                                     1
                                          1
                                                                       2
                                                                 1
                                                                                 1
           Blood Stasis-heat Syndrome YING Pian ,WANG Jiaxi ,YANG Huadi ,XU Li ,LU Shenyi ,WU Yanping 1*
           1.Department of Gynecology,the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,China
           2.Department of Anorectal Surgery,the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,
           China
           *
           Corresponding author:WU Yanping,Chief TCM physician;E-mail:Wypzzwyp@163.com
               【Abstract】 Background Adenomyosis is a difficult-to-treat gynecological disease with unclear pathogenesis,
           individualized treatment for which is extensively valued,and the integrated traditional Chinese and western medicine treatment
           has been proven to have unique benefits merits. Objective To examine the clinical efficacy of compound Daxueteng enema plus
           dydrogesterone for post-laparoscopic adenomyosis patients with blood stasis-heat syndrome. Methods Participants(n=46)
           were selected from Zhejiang Provincial Hospital of Chinese Medicine during January 2019 to August 2020. All of them received
           laparoscopic surgery,and were diagnosed with adenomyosis by pathological examination of the surgical specimen,and with
           blood stasis-heat syndrome by TCM syndrome differentiation. For comparing the effects of two types of postsurgical treatments
           lasting for three months,they were randomized into a control group (n=22) and a treatment group(n=24),receiving oral


               基金项目:国家自然科学基金资助项目(82104909);浙江省自然科学基金资助项目(LQ20H270003);浙江省中医药科技计
           划项目(2020ZB098)
               1.310006 浙江省杭州市,浙江中医药大学附属第一医院妇科 2.310006 浙江省杭州市,浙江中医药大学附属第一医院肛肠科
               *
               通信作者:吴燕平,主任中医师;E-mail:Wypzzwyp@163.com
               本文数字出版日期:2021-12-23
   108   109   110   111   112   113   114   115   116   117   118